Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.

By F. De Benedetti, H. Brunner, N. Ruperto, A. Kenwright, S. Wright, I. Calvo, R. Cuttica, A. Ravelli, R. Schneider, P. Woo and 15 more. New England Journal of Medicine, 2012

789 citations recorded by the source corpus.

Subfields: Hematology, Ophthalmology, Speech and Hearing

View Paper: https://www.semanticscholar.org/paper/f9db7d026259ecd5bc58d1835a85000c968a25a5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. S. Finotto
2. Markus F. Neurath

Citations in the corpus

• IL-6 in inflammation, immunity, and disease. (2014, background): “…100 countries (Tanaka et al. 2013), Cite this article as Cold Spring Harb Perspect Biol 2014;6:a016295 9 as well as for systemic and polyarticular juvenile idiopathic arthritis (Yokota et al. 2008, 2012; De Benedetti et al. 2012) and Castleman’s disease (Nishimoto et al. 2005) in several countries.”
• Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. (2012, neutral): “Other 1 (2) 4 (10) 19 (11) 7 (14) 7 (14)”
• The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease (2020, background): “Impressive responses to antagonism of either IL-6 or IL-1 have been reported in sJIA [6,7].”